Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 5,398 matching trials from the live ClinicalTrials.gov search.

Filters: Tucson, Arizona Clear all

Conditions: B-Cell Malignancies
Interventions: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
Interventions: No screening, Regular Screening; Other
Lead sponsor: University of British Columbia; Other
Eligibility: 18 Years and older
Enrollment: 3,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Tucson, Arizona • Washington D.C., District of Columbia

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Interventions: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 247
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo, Tobramycin solution for inhalation; Drug
Lead sponsor: Bonnie Ramsey; Other
Eligibility: 6 Months to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Asthma
Interventions: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage); Device
Lead sponsor: American Lung Association Asthma Clinical Research Centers; Other
Eligibility: 15 Years to 60 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 18
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more

Conditions: Critical Limb Ischemia
Interventions: UT-15C SR (treprostinil diethanolamine) 1mg oral tablets; Drug
Lead sponsor: Southern Arizona Vascular Institute; Other
Eligibility: 45 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Tucson, Arizona • Springfield, Illinois

Conditions: COVID-19, Sars-CoV-2 Infection
Interventions: NVX-CoV2705, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 50 Years to 65 Years
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 99
States / cities: Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pamrevlumab, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Breast Cancer
Interventions: Thermalytix; Device
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo comparator; Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 52
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more

Conditions: Achilles Tendinopathy
Interventions: NGI226, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Deerfield Beach, Florida • Houston, Texas

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide; Drug · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 311
States / cities: Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more

Conditions: Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting
Interventions: JNJ-42160443, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Birmingham, Alabama • Tucson, Arizona • Laguna Hills, California + 14 more

Conditions: Diabetic Foot Ulcer, Diabetic Foot, Diabetes
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 6 more

Conditions: Neoplasm Metastasis / Bone and Bones
Interventions: Data Collection; Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 15
States / cities: Anchorage, Alaska • Tucson, Arizona • Plantation, Florida + 12 more

Conditions: COVID-19
Interventions: Lenzilumab, Placebo, Remdesivir; Biological · Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Keratosis
Interventions: Aldara (imiquimod) cream, 5%; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more

Conditions: Alcohol-associated Liver Disease
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Peoria, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 30 more

Conditions: Migraine Disorders
Interventions: Lasmiditan; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 182
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 132 more

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 170
States / cities: Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more

Conditions: Diabetes type2, Obesity
Interventions: RESET Liner, Sham; Device · Other
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 27
States / cities: Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 65 Years
Enrollment: 72 participants
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Immunoglobulin A Nephropathy
Interventions: Povetacicept, Placebo (matched to Povetacicept); Drug
Lead sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 77
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Search by objective public record fields.

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)

UT-15C SR in the Treatment of Critical Limb Ischemia

Efficacy and Safety of NVX-CoV2705

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Novel Thermal Imaging Technique for Breast Screening

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

Radium-223 Dichloride Long-term Follow-up Program

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

The RESET System Pivotal Clinical Trial (Protocol Revision K)

MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)